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Abstract
Expression of the four transcription factors Oct4, Sox2, Klf4, and c-Myc (OSKM) is sufficient to reprogram somatic cells into
induced pluripotent stem (iPSCs). However, this process is slow and inefficient compared with the fusion of somatic cells
with embryonic stem cells (ESCs), indicating that ESCs express additional factors that can enhance the efficiency of
reprogramming. We had previously developed a method to detect and isolate early neural induction intermediates during
the differentiation of mouse ESCs. Using the gene expression profiles of these intermediates, we identified 23 ESC-specific
transcripts and tested each for the ability to enhance iPSC formation. Of the tested factors, zinc finger protein 296 (Zfp296)
led to the largest increase in mouse iPSC formation. We confirmed that Zfp296 was specifically expressed in pluripotent
stem cells and germ cells. Zfp296 in combination with OSKM induced iPSC formation earlier and more efficiently than OSKM
alone. Through mouse chimera and teratoma formation, we demonstrated that the resultant iPSCs were pluripotent. We
showed that Zfp296 activates transcription of the Oct4 gene via the germ cell–specific conserved region 4 (CR4), and when
overexpressed in mouse ESCs leads to upregulation of Nanog expression and downregulation of the expression of
differentiation markers, including Sox17, Eomes, and T, which is consistent with the observation that Zfp296 enhances the
efficiency of reprogramming. In contrast, knockdown of Zfp296 in ESCs leads to the expression of differentiation markers.
Finally, we demonstrated that expression of Zfp296 in ESCs inhibits, but does not block, differentiation into neural cells.
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Introduction
Pluripotent stem cells have the ability to differentiate into all
somatic lineages as well as germ cells, yet they fail to pattern these
lineages into a viable embryo. Additionally, pluripotent stem cells
can be directed to self-renew by the addition of particular growth
factors and can thereby be propagated as immortal cell lines.
Therefore, pluripotent stem cells can, in principle, provide a
virtually unlimited quantity of a wide variety of specialized cells
that can be used for basic research, drug discovery, and
regenerative medicine.
Pluripotent stem cells are also capable of reprogramming
somatic cells. During gastrulation, somatic cells commit to a
particular germ layer. Throughout development, somatic cells
continue to differentiate and form various specialized cells.
Differentiation can be reversed in vitro after the fusion of somatic
cells with pluripotent stem cells. The somatic genome is thereby
reprogrammed and resembles that of a pluripotent cell [1].
Somatic transcripts are downregulated and silenced, and plurip-
otent loci are demethylated and transcribed. This reprogramming
process is highly efficient and has been observed to occur within
one day of fusion [2].
In 2006, Shinya Yamanaka demonstrated that the expression of
the four transcription factors Oct4, Sox2, Klf4, and c-Myc (OSKM)
in somatic cells is sufficient to induce pluripotent stem cell (iPSC)
identity [3]. Takahashi et alia initially screened expression data for
genes specifically expressed in pluripotent stem cells [3]. Screening
of 24 candidate genes demonstrated that only four were necessary
for inducing reprogramming. Using OSKM, iPSCs have been
derived from many different of somatic cell types, including neural
stem cells (NSCs) [4,5], keratinocytes [6], and lymphocytes [7,8].
iPSCs have been shown to pass every functional test for
pluripotency, including germline transmission in chimeras and
tetraploid embryo complementation [9,10]. Using tetraploid
embryo complementation, various research groups have obtained
mice that were formed entirely from iPSCs [11,12,13,14].
However, the efficiency of iPSC formation induced by OSKM
is relatively low. The reprogramming of NSCs induced by OSKM
requires approximately 1–2 weeks [4]. In contrast, reprogrammed
cells are observed as early as 24 hours after the fusion of NSCs
with pluripotent stem cells [2,15,16]. This striking difference in
efficiency of these two reprogramming methods suggests that
pluripotent stem cells express additional factors that can enhance
reprogramming.
PLoS ONE | www.plosone.org 1 April 2012 | Volume 7 | Issue 4 | e34645We sought to identify a novel, pluripotent-specific gene that is
capable of enhancing iPSC formation. Using previously obtained
expression data, we selected 23 candidate genes and tested each
for the ability to enhance reprogramming [17]. Of the tested
factors, zing finger protein 296 (Zfp296) led to the largest increase in
iPSC formation. We confirmed that Zfp296 was specifically
expressed in pluripotent stem cells and germ cells. Zfp296 in
combination with OSKM induced iPSC formation earlier and
with greater frequency than OSKM plus an empty control vector.
Through chimera and teratoma formation, we demonstrated that
the resultant iPSCs were pluripotent. We showed that Zfp296
activates transcription of the Oct4 gene via the germ cell–specific
conserved region 4 (CR4), and increases Nanog expression when
overexpressed in ESCs. We demonstrated that Zfp296 expression
during the differentiation of ESCs inhibits neural induction.
Finally, we found that shRNA-mediated knockdown of Zfp296 in
ESCs leads to an increase in the expression of differentiation
markers, including Cdx2, Pax6, and T. Therefore, we conclude that
Zfp296 is a novel, pluripotent-specific reprogramming factor.
Results
OSKM plus Zfp296 induces reprogramming more
efficiently and faster than OSKM alone
We hypothesized that ESCs express pluripotent-specific genes
that when added individually to OSKM would enhance the
efficiency of reprogramming. Candidate reprogramming genes
were drawn from our previously published microarray data [17].
First, we filtered for genes that were expressed specifically in ESCs.
These genes were defined as those with at least a four-fold
downregulation in expression on day 4 of differentiation and the
same or even lower expression on day 7 of differentiation.
Candidate genes were required to be expressed in ESCs at a level
that was at least four-fold higher than that in NSCs. Finally,
candidate genes were selected manually for transcription factors
and chromatin regulators, as genes with these functions have
previously been shown to enhance iPSC formation. The final list
consisted of 23 candidate factors (Table 1).
Each of these 23 factors was tested individually for the ability to
enhance iPSC formation. NSCs with a transgenic Oct4-GFP
reporter construct were infected with OSKM together with one of
the candidate factors. As a control, NSCs were infected with
OSKM and an empty retroviral construct (Table 1). The number
of green fluorescent protein (GFP)-positive colonies was used as a
measure of the reprogramming efficiency and the results are
shown in Figure 1. Of our 23 tested factors, a few induced a
significant increase in the number of GFP-positive colonies. Zfp296
and Esrrb led to the largest increases in iPSC colony formation. As
Esrrb has been previously described to enhance iPSC formation,
we decided to focus on Zfp296. A few factors, such as Rhox6 and
Dmrt1, significantly inhibited iPSC colony formation.
Next, we sought to evaluate the impact of Zfp296, when added
to OSKM, on iPSC formation in greater detail. To do this, plates
of NSCs infected with either OSKM plus Zfp296 or OSKM plus
empty vector were scanned every day by using an automated
microscope, and images were scored manually for the presence of
GFP-positive colonies or stage-specific embryonic antigen 1
(SSEA1)-positive colonies. The first GFP-positive colonies were
observed on day 6 for NSCs infected with OSKM plus Zfp296,i n
contrast to 8 days for OSKM plus empty vector (Figure 2A). This
represents a 25% decrease in the time required for onset of Oct4-
GFP expression. The number of iPSCs, when scored as either
GFP-positive colonies or SSEA1-positive colonies, formed by
OSKM plus Zfp296 was higher compared with that formed by
OSKM plus empty control on all time points measured—a
significant increase of about 2 fold was consistently observed
(Figure 2A and 2B). Therefore, we conclude that Zfp296 increases
the efficiency of OSKM-induced reprogramming of NSCs into
iPSCs.
iPSCs generated with Zfp296 are pluripotent
The pluripotency of the iPSCs generated by OSKM plus Zfp296
was then evaluated. To this end, we picked individual iPSC
colonies and established individual iPSC lines from NSCs infected
with OSKM plus Zfp296. Immunostaining confirmed that the
iPSCs expressed Oct4 (Figures 3A–C). The expression of GFP
strongly suggests that the endogenous Oct4 gene had been
demethylated and is actively transcribed in the iPSCs generated
by OSKM plus Zfp296 (Figure 3D). Bisulfite sequencing results
corroborated our finding that the endogenous Oct4 promoter had
been demethylated in the iPSCs generated by infection of cells
with OSKM plus Zfp296 (Figure 4).
Next, we determined the differentiation potential of the iPSCs
using two independent in vivo assays. First, iPSCs were injected into
immunodeficient mice to form teratomas. Once tumors had
formed, they were sectioned and stained. Within individual
tumors, forming cartilage (mesoderm), neural progenitors (ecto-
derm), and epithelial cells (endoderm) were found, indicative of
iPSC differentiation into cells with fates from each of the three
germ layers (Figures 3E–G). Next, we aggregated the iPSCs with
morula-stage mouse embryos and were able to obtain chimeras
(Figure 3H). The chimeras were mated, and their offspring were
found to carry the GFP transgene, which was inherited from the
iPSCs, demonstrating germline transmission (Figure 3I). There-
fore, we conclude that the iPSCs generated by infection of cells
with OSKM plus Zfp296 are pluripotent, as they are able to
differentiate into cells with fates from all three germ layers as well
as germ cells.
Zfp296 promotes expression of pluripotency markers and
inhibits expression of differentiation markers
We next determined the expression of Zfp296 in several cell
types and organs by quantitative reverse transcriptase–polymerase
chain reaction (RT-PCR). Zfp296 was highly expressed in
pluripotent stem cells as well as germline stem (GSCs)
(Figure 5A). Significant Zfp296 expression was also detected in
the spleen—but not in the liver, kidney, heart, intestine, brain,
colon, bone marrow, lung, stomach, and skin. Zfp296 was also
expressed in human ESCs and was downregulated during ESC
differentiation (Figure 5B). This data is similar to that described in
a previous report, in which Zfp296 was found to be primarily
expressed by ESCs and testis [18]. However, while Dear and
colleagues reported that Zfp296 expression in the testis was
confined to post-mitotic sperm, we demonstrate high levels of
Zfp296 expression in GSCs [18]. Therefore, Zfp296 is mainly
expressed in pluripotent stem cells and cells of the germ cell
lineage, including GSCs.
The ability of Zfp296 to functionally increase the efficiency of
iPSC formation suggests that the factor may interact with the
regulatory elements of pluripotent genes. The expression pattern
of Zfp296 was specific to pluripotent stem cells and germ cells,
which is similar to the expression pattern of Oct4. As such, we
hypothesized that Zfp296 might directly activate transcription via
Oct4 regulatory elements. To test this, we performed a luciferase
assay with evolutionary conserved regions of the Oct4 promoter
(Figure 6A). We observed that both Nanog and Zfp296 activated
transcription from conserved region 4 of the Oct4 promoter. Of
significant interest is the finding that this distal enhancer element is
Zfp296, a Pluripotency Gene
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of pre-implantation embryos, ESCs, and germ cells, all of which
also express Zfp296 [19,20].
Next, we evaluated the effects of Zfp296 overexpression in
mouse ESCs. To this end, an inducible Zfp296 vector under the
control of tetracycline was introduced into ESCs. 18 hours after
induction, transgenic Zfp296 RNA was upregulated by 40 fold
(Figure 6B). Quantitative RT-PCR revealed that at 18 hours,
Nanog expression was more than 2-fold upregulated (Figure 6C).
However, the expression of other pluripotency-associated genes,
such as Sox2 and Klf4, was not affected by transgenic Zfp296.
Prolonged induction of transgenic Zfp296 led to a morphologic
change in the cultured ESC colonies—homogeneously round
colonies with a smooth border and surface that indicated
improved quality of the ESCs. Consistent with this observation,
three markers for differentiation, Eomes, Pax6 and T, were all
significantly downregulated in the Zfp296-induced ESCs. There-
fore, we conclude that Zfp296 directly activates transcription of the
Oct4 gene, and leads to upregulation of Nanog expression in ESCs.
These results are consistent with the observation that Zfp296
enhances the efficiency of reprogramming induced by OSKM.
As Zfp296 overexpression in ESCs led to Nanog upregulation, we
assessed whether Zfp296 overexpression would affect the mainte-
nance of ESC pluripotency and inhibit ESC differentiation. The
transgenic ESCs were plated under neural induction conditions in
the presence or absence of induced Zfp296 expression (Figure 6D).
On day 7 of differentiation, the expression of pluripotency markers
Oct4, Sox2, and Rex1 was slightly higher and that of the neural
differentiation markers Pax6 and Sox1 was lower in ESCs
overexpressing transgenic Zfp296 compared with uninduced cells.
This result demonstrates that Zfp296 expression mildly inhibits
ESC differentiation, but it is not sufficient to prevent it.
In our final experiment, lentiviral shRNA–mediated knockdown
of Zfp296 was used to determine the role of Zfp296 in the self-
renewal of ESCs. Two constructs with different targeting
sequences each resulted in a knockdown of approximately 85%
compared with a scrambled control (Figure 7A). Both constructs
resulted in upregulation of the differentiation markers Cdx2, Pax6,
and T in ESCs compared with the scrambled control (Figure 7B).
Although Zfp296 shRNA1 caused downregulation of the expres-
sion of the pluripotency markers Prdm14, Rex1, and Nanog, the
effects of Zfp296 shRNA2 on pluripotent gene expression were
Table 1. Candidate reprogramming factors.
Expression Relative to ESCs Clone #
1 Average #GFP+ colonies
2
Day 4 Day 7
Zfp296 0.23 0.13 I.30936046 97
Esrrb 0.06 0.05 I.40130872 95
Suv39h1 0.12 0.13 I.5352230 90
Tex19 0.04 0.01 n.a./RT-PCR 69
Nr0b1 0.03 0.02 R.C330034L04 61
Rex2 0.03 0.02 I.30462971 58
Tcfcp2l1 0.13 0.12 I.40087602 57
Piwil2 0.13 0.09 I.40131020 46
Gm817 0.10 0.06 R.4932441K12 46
Qkf 0.25 0.26 gift
3 46
LOC435970 0.02 0.01 R.I1C0022H11 45
Mael 0.11 0.01 I.6744032 42
Prdm14 0.06 0.06 R.**
4 41
2610305D13Rik 0.20 0.04 R.2610305D13 41
Zhx1 0.21 0.18 I.6406286 36
LOC195331 0.07 0.07 I.30044792 35
Cdyl2 0.06 0.07 I.5690642 32
4933405K07Rik 0.18 0.10 R.4933405K07 32
Mmip2 0.07 0.04 n.a./RT-PCR 26
Grhl3 0.20 0.24 I.3067679 22
Phf17 0.21 0.13 I.5250231 13
Dmrt1 0.10 0.05 I.40129989 12
Rhox6 0.14 0.15 I.30790014 10
empty n.a. n.a. n.a. 41
The 23 candidate reprogramming factors are listed, along with their expression, in differentiated ESCs according to the original array data. Also listed is the cDNA clone
used for subcloning into the pMX retroviral expression vectors and the average number of Oct4-GFP–positive iPSC colonies obtained after infection of NSCs with the
expression vector in combination with OSKM.
1First initial signifies either IMAGE (I) or Riken (R). Indicated genes were isolated by RT-PCR on ESC RNA.
2Tested on NSCs in combination with Oct4, Sox2, Klf4 and c-Myc.
3Qkf cDNA clone was a generous gift from Dr. Tim Thomas.
4PRDM14 was combined from two Riken clones: 6030400A03 and C330011M19 using an internal EcoRI site.
doi:10.1371/journal.pone.0034645.t001
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reduced Zfp296 expression. Although our previous luciferase and
overexpression results would have predicted a different outcome, it
is possible that residual Zfp296 is sufficient for regulating the CR4
enhancer of Oct4 in ESCs, or that other factors present in ESCs
compensate for the lack of Zfp296. It is also possible that Zfp296
plays a more significant role in regulating Oct4 expression from
CR4 in GSCs. These data show that reduced Zfp296 expression in
ESCs leads to an increase in the expression of markers for
differentiation, but this Zfp296 reduction is not sufficient to
prevent ESC self-renewal.
Discussion
Somatic cell differentiation and fate commitment can be
reverted to pluripotency through reprogramming. After fusion of
a somatic cell with a pluripotent stem cell, such as an ESC, the
somatic cell genome undergoes reprogramming within 24 hours
[2]. However, reprogramming mediated by the expression of
OSKM requires significantly longer. Therefore, ESCs appear to
express additional factors that can enhance the efficiency of
reprogramming induced by OSKM. In this study, we sought to
identify some of these factors.
We postulated that such additional reprogramming factors
would be expressed specifically in ESCs. Using microarray data
from ESCs undergoing early neural differentiation, we identified
transcripts specifically expressed in undifferentiated ESCs. As all
four of the reprogramming genes discovered by Takahashi et alia
are transcription factors, we focused on transcription factors and
chromatin regulators. A final list of 23 ESC-specific genes was
selected, and these genes were each cloned into retroviral
expression vectors to test for the ability to increase the number
of iPSCs formed by OSKM.
Of the 23 genes tested, Zfp296 led to the largest increase in the
number of iPSC colonies formed when combined with OSKM.
While the NSCs infected with OSKM expression vectors plus an
empty vector consistently formed Oct4-GFP–positive colonies on
day 8, cells infected with OSKM plus Zfp296 expression vectors
formed significant numbers of Oct4-GFP–positive colonies on day
6, with an overall 2-fold increase in iPSC colony formation
observed in cultures infected with OSKM plus Zfp296 compared
with those infected with OSKM plus empty vector. Therefore, the
addition of Zfp296 to OSKM induces reprogramming more
efficiently and faster than OSKM alone.
We confirmed that the iPSCs formed by OSKM plus Zfp296
expression are pluripotent. First, the iPSCs were found to
appropriately express the pluripotent marker Oct4. When the
iPSCs were injected into immunodeficient mice, teratomas formed
containing cells derived from all the three germ layers: ectoderm,
mesoderm, and endoderm. Finally, chimeras formed from the
iPSCs that had been aggregated with morula-stage embryos.
When these chimeras were mated, germline transmission of the
GFP transgene was detected. Therefore, we conclude that Zfp296
enhances OSKM-induced reprogramming into bona fide pluripo-
tent stem cells.
The present study indicates that Zfp296 is expressed specifically
in pluripotent cells and germ cells, and is part of the pluripotent-
specific transcriptional network. Previous work has shown that
Zfp296 is expressed in ESCs and post-mitotic sperm [18]. We have
extended these results by showing that Zfp296 is also expressed in
pluripotent epiblast stem cells, GSCs, and human ESCs.
Figure 1. Candidate reprogramming factor testing results. Number of Oct4-GFP–positive iPSC colonies formed by NSCs infected with OSKM
plus the designated factor relative to OSKM plus an empty retroviral vector. Mean and standard deviations are shown, and p values were calculated
with t-tests.
doi:10.1371/journal.pone.0034645.g001
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Moreover, we have shown that Zfp296 directly activates
transcription of the Oct4 promoter using the element that is
responsible for Oct4 expression in both ESCs and germ cells—
CR4. Overexpression of Zfp296 in ESCs resulted in increased
expression of the pluripotency gene Nanog and decreased
Figure 2. Timing and efficiency of iPSC colony formation. NSCs were infected with either OSKM+Zfp296 or with OSKM+empty vector. GFP-
positive colonies from 30 fields from an automated microscope were counted in three independent replicates for each of the days shown (A). SSEA1-
positive colonies from 60 fields from an automated microscope were counted in three independent replicates for each of the days shown (B). Mean
and standard deviations are shown, and P values were calculated with t-tests.
doi:10.1371/journal.pone.0034645.g002
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relative to uninduced cells. This finding suggests that Zfp296 plays
an important role in both pluripotent stem cells and germ cells.
Zfp296 has been detected at significant levels in the transcriptome
of oocytes and 4-cell–stage embryos, suggesting that Zfp296 may
promote the activation of zygotic Oct4 expression after fertilization
[21].
Figure 3. Pluripotency of iPSCs induced with OSKM+Zfp296. An iPSC line induced with OSKM+Zfp296 is shown in phase (A), DAPI (B), Oct4
immunostained (C), or Oct4-GFP (D). Teratomas formed with this iPSC line were composed of cartilage (mesoderm; E), neural rosettes (ectoderm; F),
and epithelia (endoderm; G). A chimera formed with this iPSC line is shown (H), and offspring from this chimera carried the GFP transgene, which
originated from the iPSCs (I).
doi:10.1371/journal.pone.0034645.g003
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Zfp296 levels resulted in an upregulation of differentiation
markers. However, we did not observe a consistent reduction in
Nanog and Oct4 levels. This was surprising given that Zfp296
stimulated transcription of CR4 in a luciferase assay and that
Zfp296 overexpression in ESCs increased Nanog expression.
However, this discrepancy might be explained by residual
expression of Zfp296. Another possibility is that ESCs express
other factors that compensate for the lack of Zfp296. It is also
possible that Zfp296 plays a more important role in the regulation
of Oct4 expression in GSCs than ESCs. Therefore, we conclude
that Zfp296 is a novel pluripotent-specific transcription factor that




This study did not involve human participants. All experiments
involving animals (e.g. cell transplantation) were carried out in
accordance with local institutional guidelines under the protocol
87-51.04.2010.A387, which was approved by Landesamt fu ¨r
Natur, Umwelt und Verbraucherschutz of the state of North
Rhine-Westphalia, Germany. In vitro experiments were carried out
with existing cell lines obtained from previous studies. The
appropriate citations are given next to each cell line in the
Materials and Methods.
Microarray data
The OG2 ESCs, which were used to collect the expression data,
were derived in the laboratory of Prof. Dr. Hans Scho ¨ler, as
previously reported [17]. The differentiation, expression data
collection, and original analysis of the microarray data have also
Figure 4. Oct4 promoter methylation. Bisulfite sequencing results
assessing the DNA methylation status of the Oct4 promoter is shown for
the indicated cell types. OSKM=Oct4, Sox2, Klf4, and c-Myc; ESCs=em-
bryonic stem cells; NSCs=neural stem cells. Open and filled circles
represent unmethylated and methylated CpGs, respectively.
doi:10.1371/journal.pone.0034645.g004
Figure 5. Specificity of Zfp296 expression. Quantitative real-time RT-PCR results are shown for Zfp296 using RNA from the indicated mouse
sources (A) and indicated human ESC-derived cells (B). EpiSCs=epiblast stem cells; ESCs=embryonic stem cells; GSCs=germline stem cells;
TSCs=trophoblast stem cells.
doi:10.1371/journal.pone.0034645.g005
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on four main considerations. First, genes had to be either present
or marginally expressed in ESCs as defined by the Affymetrix
scoring system. Second, genes had to have at least 4-fold
downregulation of expression on day 4 of differentiation compared
with (undifferentiated) ESCs. Third, genes had to have lower or at
most 2-fold higher expression levels on day 7 of differentiation
compared with day 4. Fourth, the genes had to have at least 4-fold
higher expression in ESCs compared with NSCs. In addition, the
final candidates were chosen manually based on their identifica-
tion as either transcription factors or chromatin factors. A few
genes, such as Piwil2, were chosen based on a combination of
specific expression and known function of potential relevance to
reprogramming, despite not being transcription factors or
chromatin regulators. Factors that were part of the original screen
by Takahashi et alia [3] were not considered for selection.
Candidate reprogramming factor cloning
Whenever possible, cDNA clones were obtained commercially
(Table 1). IMAGE clones were preferred and purchased from
Open Biosystems. Riken clones were obtained from the FAN-
TOM collection using DNAFORM. The inserts from these
original cloning vectors were isolated by restriction digestion and
ligated into the pMX vectors [22]. Dr. Tim Thomas kindly
provided the Qkf clone. Tex19 and Mmip2 were amplified from
ESC cDNA using PCR and cloned into pMXs. The ESCs have
been described previously, and were derived from preimplantation
mouse embryos [17].
The Zfp296 clone from the IMAGE consortium contained a
sequence-verified point mutation (C262T) that resulted in an
amino acid change (T88I). This mutation was corrected using site-
specific mutagenesis. Primers were designed using the Quikchange
primer design webtool (Agilent; https://www.genomics.agilent.
com) and used to amplify the corrected version directly from the
IMAGE clone. This PCR product was then used to transform E.
coli, and individual clones were picked and sequenced to confirm
correction.
iPSC formation assay
The NSCs used in this study were derived by the laboratory of
Prof. Dr. Hans Scho ¨ler and have been reported previously [17].
Retroviral packaging was performed using PlatinumE cells (Cell
Biolabs) transfected with a complex of 9 ml of Fugene 6 (Roche
Applied Science) and 3 mg of the retroviral plasmid to be
packaged. PlatinumE medium consisted of DMEM (Invitrogen),
16penicillin/streptomycin/glutamine (Invitrogen), and 10% fetal
calf serum (FCS; PAA). Two days later, the supernatant was
collected and filtered. 50,000 OG2 NSCs were seeded the day
before infection on gelatin-coated 6-well plates (Sarstedt) and fed
with NSC medium. NSC medium consisted of DMEM/F12
supplemented with N2 supplement, 10 ng/ml epidermal growth
factor (EGF), 10 mg/ml basic fibroblast growth factor (bFGF),
50 mg/ml BSA (Fraction V), and 16 penicillin/streptomycin/
glutamine (all from Invitrogen). For infection, 100 ml of each of the
retroviral supernatants for Oct4, Sox2, Klf4, and c-Myc as well as
200 ml of the supernatant for the factor being tested was added to
the pre-seeded NSCs. NSC medium was added to a total of 2 ml.
Protamine sulfate was added to a final concentration of 6 mg/ml,
and the entire mixture was added to the NSCs. After 24 hours,
infected cells were washed three times with PBS and fed with fresh
NSC medium. Two days later, the cells were again fed with NSC
medium. Two days after that, the infected cells were fed with
FFES cell medium, and the medium was changed every other day
thereafter. FFES medium consisted of Knock-Out DMEM, 16%
Figure 6. Zfp296 activates transcription from the Oct4 promot-
er. Zfp296 and Nanog were tested by luciferase assays for transactiva-
tion of Oct4 promoter fragments (A). The P value for Zfp296-induced
transcription from CR4 compared with control was less than 0.1, as
shown. CR1, CR2, CR3, and CR4=evolutionary conserved regions 1, 2, 3,
and 4, respectively, as defined by Nordhoff et alia [20]. ESCs were
induced to express Zfp296 for 18 hours followed by quantitative RT-PCR
to assess the expression of transgenic Zfp296 (B) and indicated marker
genes (C) compared with uninduced cells (B). Expression of indicated
marker genes on day 7 of neural differentiation in the presence of
induced Zfp296 expression relative to uninduced cells (D).
doi:10.1371/journal.pone.0034645.g006
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nonessential amino acids (Invitrogen), 1% penicillin/streptomy-
cin/glutamine (Invitrogen), 1% beta-mercaptoethanol (fresh 1006
stock solution made by diluting 7 ml of 14.3 M beta-mercapto-
ethanol [Sigma-Aldrich] in 10 ml PBS [Invitrogen]) and 2,000
units/ml of LIF. Images of GFP-positive colonies were captured
on an ArrayScan VTI automated microscope (Thermo) and the
number of such colonies were counted manually. 30 images for
each day were counted from three independent replicates. For
SSEA1, cells infected with the indicated factors in 6-well plates
were immunostained and the images captured by the ArrayScan
VTI. 60 on each day were counted from three independent
replicates.
iPSC culture
All iPSC lines reported in this study are novel cell lines that were
derived from NSCs as described above. These NSCs, as already
indicated, were created in the laboratory of Prof. Dr. Hans Scho ¨ler
and have been reported previously [17]. As these iPSC lines are
the derivatives of already established cell lines, neither a new
animal protocol nor other approval is necessary. iPSCs were as
described above and cultured on irradiated mouse embryonic
fibroblasts in ESC medium, which consisted of Knock-Out
DMEM (Invitrogen), 20% FCS (PAA), 1% nonessential amino
acids (Invitrogen), 1% penicillin/streptomycin/glutamine (Invitro-
gen), 1% beta-mercaptoethanol (fresh 1006 stock solution made
by diluting 7 ml of 14.3 M beta-mercaptoethanol [Sigma-Aldrich]
in 10 ml PBS [Invitrogen]) and 2,000 units/ml of LIF. Oct4
promoter methylation was analyzed as described previously [23].
The mouse embryonic fibroblasts (MEFs) used in this study were
derived in the laboratory of Prof. Dr. Hans Scho ¨ler and have been
reported previously [17].
Human ESC culture
The human ESC line HUES6 was purchased from the hESC
Collection (Harvard University). The derivation of this line has
been reported previously [24]. For differentiation, we used the
previously published protocol for motor neuron differentiation by
Chambers et alia [25].
Zfp296 Knockdown
Lentiviral shRNA lentiviral knockdown constructs (Sigma:
TRCN0000095891 [shRNA1] and TRCN0000095892
[shRNA2]) were produced in 293T cells (ATCC). Cells were
transfected with 3 mg of the shRNA construct, 2 mg psPax2
(Addgene 12260), and 1 mg pMD2.G (Addgene 12259) using 18 ml
Fugene 6 reagent (Promega). After 3 days, the viruses were
concentrated by ultracentrifugation (26,000 rpm, 2 hours, 4uC)
and resuspended in 1 ml of DMEM low glucose (PAA). 1610
4
ESCs were subsequently infected with 100 ml of concentrated
virus, and RNA samples were taken 3, 4, and 7 days after
infection. To increase the fraction of infected cells, puromycin
selection (1 mg/ml) was started on day 4. As a negative control and
for normalization of the real-time PCR analysis, a homemade
scrambled shRNA lentivirus was used. For the scrambled
knockdown plasmid, the LVTHM plasmid (Addgene 12247) was
used as the backbone, with GFP replaced with RFP Tomato [26].
Scrambled shRNA was cloned using ClaI/MluI (both from NEB),
with the sequence corresponding to Ito et alia 2010 [27].
Immunostaining
Cells were fixed with paraformaldehyde and permeabilized with
Triton X-100. After blocking, cells were stained overnight as
indicated. The Oct4 antibody was obtained from Santa Cruz
Biotechnology. Secondary antibody staining with AlexaFluor-
conjugated antibodies (Invitrogen) was performed the following
day. The SSEA1 antibody was obtained from the Developmental
Studies Hybridoma Bank (DSHB).
Real-time RT-PCR
Stem cell marker expression in iPSCs was performed at passages
8 and 10. Total RNA was isolated using the MicroPrep Kit from
Zymo Research with on-column DNase I digestion. Reverse
transcription was performed using the Multiscribe Reverse
Figure 7. Zfp296 knockdown in ESCs. Lentiviral shRNA constructs were packaged and used to infect ESCs. Puromycin was added to select for
infected cells beginning on day 4. Efficiency of Zfp296 knockdown is shown on the indicated days after infection (A). Quantitative RT-PCR results are
shown for the indicated genes on day 7 after infection (B).
doi:10.1371/journal.pone.0034645.g007
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determined using the ABI PRISM 7900HT Sequence Detection
System (Applied Biosystems) and the SYBR green master mix
(Bio-Rad). The GSCs used in this study were derived in the
laboratory of Prof. Dr. Hans Scho ¨ler and have been reported
previously [28].
Aggregation with zona-free embryos
Cells were aggregated and cultured with denuded post-
compacted 8-cell–stage mouse embryos as reported with a slight
modification [29]. Briefly, 8-cell embryos were flushed from
[(C57BL/66C3H) F1 female mice6CD1 male mice] at 2.5 days
post coitum (dpc) and placed in M2 medium (Hogan et al., 1986).
Clumps of loosely connected cells (10–20 cells each) with short
trypsin treatment were chosen and transferred into microdrops of
KSOM medium with 10% FCS under mineral oil; each clump
was placed in a depression in the microdrop. Meanwhile, batches
of 30–40 embryos were briefly incubated in acidified Tyrode’s
solution [30] until dissolution of their zona pellucida. A single
embryo was place on the clump. All aggregates were assembled in
this manner and cultured overnight at 37uC, 5% CO2. After
24 hours of culture, the majority of aggregates had formed
blastocysts. We transferred 11–14 embryos into each uterine horn
of 2.5-dpc pseudopregnant recipients.
Teratoma analysis
For the teratoma formation assay ,5610
6 cells were injected
subcutaneously into the flank of severe combined immunodefi-
ciency (SCID) mice. After 4–5 weeks, the teratoma that had
formed was excised, fixed in 4% paraformaldehyde, and subjected
to histological examination with hematoxylin and eosin staining.
Luciferase assay
Transactivation activity was measured using the Dual-Glo
Luciferase Assay System (Promega), following the manufacturer’s
instructions. Briefly, 1610
5 293T cells were plated onto a 24-well
plate and transfected with Fugene 6 (Roche). The plasmid DNA
consisted of 100 ng of effector DNA (pMX Zfp296, pMX Nanog),
100 ng of pTK-RL (Promega), and 800 ng of pGL3 promoter
vector (Promega) containing conserved regions (CR1–4), respec-
tively (Nordhoff et al., 2000). Luciferase activity was measured
after 48 hours post-transfection and normalized against the
Renilla luciferase activity.
Induction of transgenic Zfp296 transcription in ESCs
The overexpression of Zfp296 in ESCs was achieved through an
improved Tet-On system previously described by Anastassiadis et
alia [31]. As a starting point, OG2 ESCs, which carry the
OG2_Oct4-GFP transgene, were used. As stated above, these
ESCs were derived in the laboratory of Prof. Dr. Hans Scho ¨ler
and have been reported previously [17]. The transactivator and
the tet-responsive Zfp296 transgenes were both sequentially
electroporated into the cells by using the Nucleofection II device
from Amaxa. The procedure was performed according to the
manufacturer’s instructions, and subsequent selection was done
with puromycin (1 mg/ml; Sigma P8833) for the transactivator and
with hygromycin (200 mg/ml; Roth Cp12.2) for the tet-Zfp296
transgene. After a clonal cell line was established, the transgene
could be induced by the addition of 2 mg/ml doxycycline (Sigma
D9891) and 5610
26 M dexamethasone (Sigma D1756) to the
culture medium.
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